A House subcommittee on Tuesday held a hearing on the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act, which seeks to restructure pharmacy benefits for the Federal Employee Health Benefits Program. "We are concerned that [Lynch's] bill legislates PBM pricing and purchasing terms for FEHBP carriers. Requiring the use of specific contracting models and pricing methods via legislation will not allow the program flexibility in an industry where business practices are rapidly evolving," OPM's Director of Planning and Policy Analysis John O'Brien said. PCMA said the proposal "would undermine many of the cost-saving tools used in FEHBP and disrupt prescription drug benefits for 8 million federal employees, retirees and their families."

Related Summaries